Latest Lakefront Biotherapeutics News & Updates

See the latest news and media coverage for Lakefront Biotherapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Lakefront Biotherapeutics

Biopharmaceutical company developing acquired clinical-stage medicines

lakefrontbio.com

Headquarters: Mechelen, Belgium
Founded year: 1999
Company type: Public company
Number of employees: 60–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Lakefront Biotherapeutics

In short: Lakefront Biotherapeutics rebranded from Galapagos, completed the Ouro Medicines acquisition, and initiated a €50 million share buyback.

Company announcements

September 1 Lakefront Biotherapeutics

Lakefront Biotherapeutics has completed another tranche of share repurchases

The company acquired 127,796 shares between August 24 and 28 for approximately €3.2 million across multiple European trading venues.

August 10 Lakefront Biotherapeutics

Lakefront Biotherapeutics shares half-year 2026 financial results and business updates

The firm completed its Ouro acquisition with Gilead, maintains roughly €2 billion in cash, reports a €16.6 million net profit, and initiates a €50 million share buyback program.

July 21 Lakefront Biotherapeutics

Lakefront Biotherapeutics repurchased 98,648 shares

Under a program announced June 9, the repurchase was executed between July 13-17 at an average price of €26.00 per share.

July 13 Lakefront Biotherapeutics

Lakefront announces Paulo Fontoura has resigned from its board

He resigned after being appointed Global Head of R&D at Sanofi. Chairman Gino Santini thanked him and plans to appoint a successor.

Media coverage

Today Yahoo Finance

Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) said it plans to begin registrational studies next year ...

September 9 The Globe and Mail

Lakefront Biotherapeutics boosts buyback as it advances autoimmune pipeline

Galapagos ( (NL:LKFT) ) just unveiled an announcement.

September 9 The Globe and Mail

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Lakefront Biotherapeutics (LKFT) and BioNTech SE (BNTX)

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

August 24 Morningstar

Lakefront Biotherapeutics Autoimmune Disorder Pemphigus Treatment Gets FDA Orphan Drug Designation

"We're excited by the U.S. FDA's award of orphan drug designation for gamgertamig for the treatment of pemphigus as we continue to advance it for...

Never miss news about Lakefront Biotherapeutics

Track Lakefront Biotherapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Lakefront Biotherapeutics competitors & trending companies

Browse news for competitors to Lakefront Biotherapeutics and other trending companies.